Advances in Bioreactor Systems for the Production of Biologicals in Mammalian Cells

Abstract With the steady advancement of medicine and the healthcare industry, the demand for recombinant biotherapeutics drugs and vaccines has increased in the last two decades. This has put substantial pressure on the biopharma industry to meet the increasing need for treatment of prevailing and new diseases. Different technologies and bioreactor designs have been developed over the years to ensure safe and economical manufacturing of biopharmaceutical products by attaining high cell densities and longevities for extended periods of time. Bioreactors are the backbone of the bioprocessing industry albeit each bioreactor design has its advantages and disadvantages. A comprehensive design suitable for wide varieties of cell lines to produce high‐yielding products with the lowest cost and risk in the shortest span of time is sought. This paper focuses on evaluating the engineering aspects of currently available bioreactor designs and their suitability for mammalian cell cultures.